StockFin.ai Try Free →

Blue Jet Healthcare Limited (BLUEJET)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 16 June 2026

₹504.3 ↓ 46.27% (1Y)

🎯 Key Takeaways

Blue Jet Healthcare is in a strategic reinvestment phase following a period of revenue contraction, shifting focus from legacy API/PI to high-growth contrast media and new product launches. Despite an 8% YoY revenue decline in FY26, the company is debt-free with strong liquidity and plans to accelerate capex to ₹400 crores in FY27 to scale operations in Vizag and launch new products.
⚠️ Revenue decline in core PI/API segments poses near-term top-line pressure despite growth in contrast media.

Market Cap

₹7,466

P/E Ratio

25.4

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About BLUEJET 📊 Interactive Charts

📖 The Story

Blue Jet Healthcare is in a strategic reinvestment phase following a period of revenue contraction, shifting focus from legacy API/PI to high-growth contrast media and new product launches. Despite an 8% YoY revenue decline in FY26, the company is debt-free with strong liquidity and plans to accelerate capex to ₹400 crores in FY27 to scale operations in Vizag and launch new products. Management views this as a foundation for double-digit growth, supported by validated demand and new customer trials, particularly in international markets.

📰 What's Happening

In FY26, contrast media revenue grew 23% YoY to ₹495 crores, emerging as a key growth driver amid overall revenue decline. Management announced a significant capex acceleration to ₹400 crores in FY27 for Vizag plant expansion and new product launches, with ramp-up expected over 24-30 months. The Board has authorized a fund raise of up to ₹10,000 million via QIP or other instruments, with a 5% discount cap, to finance growth without immediate promoter dilution. An EGM is scheduled for June 17, 2026 to seek shareholder approval for the capital raise and other matters.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management expressed confidence in achieving double-digit growth in FY27, driven by new product launches and validated demand in contrast media and new therapeutic segments. They highlighted the progress of the Vizag plant ramp-up, expected to be completed within 24-30 months, as a critical enabler of expanded capacity. Capex of ₹400 crores is positioned to support this growth trajectory, with temporary investments in approved instruments planned until funds are deployed. Management emphasized operational resilience and strategic positioning in high-growth areas despite near-term macro headwinds.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Revenue decline in core PI/API segments poses near-term top-line pressure despite growth in contrast media. 2. Execution risks around Vizag plant ramp-up within 24-30 months could delay anticipated capacity gains. 3. Macro cost pressures from logistics and crude oil may continue to impact margins. 4. The proposed fund raise of ₹10,000 million may dilute existing shareholders if executed at scale, particularly if pricing or terms are unfavorable. 5. Dependence on new product launches and international customer trials introduces execution and regulatory risk.

📋 Recent Filings

🧠 Analyst's Read

Blue Jet Healthcare is repositioning for growth through strategic capex and focus on high-margin contrast media, but near-term profitability remains under pressure from volume declines and macro costs. Investors should monitor the progress of the Vizag expansion, execution of the fund raise, and early traction from new product launches and international markets. The company’s financial resilience supports its growth agenda, but operational execution will be critical to achieving sustained double-digit growth.

Based on filing content and financial data. Not a recommendation.

✨ Deep Dive with AI on BLUEJET

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.